Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse MKT  >  CEL-SCI Corporation    CVM

Delayed Quote. Delayed  - 07/01 09:58:31 pm
0.46 USD   --.--%
06/07 CEL SCI : NEW STORY CEL-SCI to Present at LD Micro Invitational
06/07 CEL SCI : to Present at LD Micro Invitational
06/01 CEL SCI : NEW STORY CEL-SCI Reports Monthly Patient Enrollment in Ma..
SummaryQuotesChartsNewsCalendarCompanyFinancialsRevisions 
News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

CEL SCI : to Present at the Fifth Annual Marcum MicroCap Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
06/09/2016 | 09:08pm CEST

By a News Reporter-Staff News Editor at AIDS Weekly -- CEL-SCI Corporation (NYSE MKT: CVM), a late-stage cancer immunotherapy company, announced that it will be a featured presenter at the 5th Annual Marcum MicroCap Conference on Thursday, June 2, 2016 in New York City at the Grand Hyatt Hotel. The Company presentation by Geert Kersten, Chief Executive Officer, is scheduled to begin at 10:30 a.m. ET (see also CEL-SCI Corporation).

The annual Marcum MicroCap Conference is a signature showcase for superior quality, under-followed public companies with less than $500 million in market capitalization. For more information or to register, please visit the conference website at http://www.marcumllp.com/microcap. About the Marcum MicroCap Conference Marcum LLP is one of the largest independent public accounting and advisory services firms in the nation, with offices in major business markets throughout the U.S., Grand Cayman and China. Headquartered in New York City, Marcum provides a full spectrum of traditional tax, accounting and assurance services; advisory, valuation and litigation support; and an extensive range of specialty and niche industry practices. The Firm serves both privately held and publicly traded companies, as well as high net worth individuals, private equity and hedge funds, with a focus on middle-market companies and closely held family businesses. In 2015, Marcum's SEC Services Practice group led all non-"Big Four" accounting firms in the performance of audits in connection with Initial Public Offerings ("IPOs"). Marcum is a member of the Marcum Group, an organization providing a comprehensive array of professional services. For more information, visit www.marcumllp.com. About CEL-SCI Corporation CEL-SCI's work is focused on finding the best way to activate a patient's immune response to fight cancer and infectious diseases. CEL-SCI believes that we should give the immune system the best chance of successfully fighting cancer by administering a cancer immunotherapy drug before surgery, radiation and chemotherapy, a time when the immune system is thought to be strongest. The typical cancer immunotherapy drug development path involves giving a cancer immunotherapy after these conventional treatments.

Its lead investigational therapy, Multikine* (Leukocyte Interleukin, Injection), is currently being studied in a pivotal Phase 3 clinical trial as a potential neoadjuvant treatment for patients with squamous cell carcinoma of the head and neck. Almost 800 patients were enrolled in that study at the end of April 2016. If the study endpoint, which is a 10% improvement in overall survival of the subjects treated with the Multikine treatment regimen plus the current standard of care (SOC) as compared to subjects treated with the current SOC only, is satisfied, the study results will be used to support applications that the Company plans to submit to regulatory agencies in order to seek commercial marketing approvals for Multikine in major markets around the world.

Additional clinical indications for Multikine that are being investigated include the treatment of cervical dysplasia in HIV/HPV co-infected women, and the treatment of peri-anal warts in HIV/HPV co-infected men and women. A Phase 1 trial of the former indication has been completed at the University of Maryland. The latter indication is now in a Phase 1 trial in conjunction with the U.S. Naval Medical Center, San Diego, under a CRADA and UCSF.

CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology as a potential vaccine for the treatment of rheumatoid arthritis.

Keywords for this news article include: HIV/AIDS, Oncology, Immunology, RNA Viruses, Retroviridae, Immunotherapy, HIV Infections, Cancer Vaccines, Immunomodulation, Vertebrate Viruses, CEL-SCI Corporation, Primate Lentiviruses, Hemic and Immune Systems, Clinical Trials and Studies, Viral Sexually Transmitted Diseases.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2016, NewsRx LLC

(c) 2016 NewsRx LLC, source Health Newsletters

share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on CEL-SCI CORPORATION
06/09 CEL SCI : to Present at the Fifth Annual Marcum MicroCap Conference
06/07 CEL SCI : NEW STORY CEL-SCI to Present at LD Micro Invitational
06/07 CEL SCI : to Present at LD Micro Invitational
06/02 CEL SCI : Announces the Closing of Its $5 Million Registered Direct Offering
06/01 CEL SCI : NEW STORY CEL-SCI Reports Monthly Patient Enrollment in May for Its Ph..
06/01 CEL SCI : Reports Monthly Patient Enrollment in May for Its Phase 3 Head and Nec..
05/31 CEL SCI : NEW STORY CEL-SCI to Present At the Fifth Annual Marcum Microcap Confe..
05/31 CEL SCI : to Present at the Fifth Annual Marcum MicroCap Conference
05/24 CEL SCI : NEW STORY CEL-SCI Announces the Closing of Its $5 Million Registered D..
05/24 CEL SCI : Announces the Closing of Its $5 Million Registered Direct Offering
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials